65,517 Shares in Altimmune, Inc. (NASDAQ:ALT) Purchased by Marshall Wace LLP

Marshall Wace LLP acquired a new stake in shares of Altimmune, Inc. (NASDAQ:ALT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 65,517 shares of the company’s stock, valued at approximately $472,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ALT. Invesco Ltd. boosted its holdings in Altimmune by 679.2% in the 4th quarter. Invesco Ltd. now owns 247,086 shares of the company’s stock worth $1,781,000 after buying an additional 215,375 shares during the period. Virtu Financial LLC bought a new position in Altimmune in the 3rd quarter worth about $674,000. Wells Fargo & Company MN boosted its stake in Altimmune by 69.3% in the 4th quarter. Wells Fargo & Company MN now owns 215,538 shares of the company’s stock worth $1,554,000 after purchasing an additional 88,209 shares during the period. Barclays PLC increased its position in shares of Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the period. Finally, Summit Financial Wealth Advisors LLC increased its position in shares of Altimmune by 116.7% during the fourth quarter. Summit Financial Wealth Advisors LLC now owns 99,488 shares of the company’s stock valued at $717,000 after buying an additional 53,570 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Trading Up 11.6 %

Shares of Altimmune stock opened at $5.77 on Friday. The business’s 50-day moving average price is $5.16 and its 200-day moving average price is $6.65. The firm has a market capitalization of $444.37 million, a PE ratio of -3.72 and a beta of 0.91. Altimmune, Inc. has a 12 month low of $3.55 and a 12 month high of $11.16.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. As a group, analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Gregory L. Weaver bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $52,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on ALT shares. Stifel Nicolaus assumed coverage on shares of Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price on the stock. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Altimmune presently has an average rating of “Buy” and an average price target of $20.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.